购物车
  • TargetMol
    您的购物车当前为空

Zafirlukast

一键复制产品信息
Rating icon 很棒

纯度: 99.83%

货号 T6736Cas号 107753-78-6

别名 扎鲁司特, Vanticon, ICI 204219, Accolate

Zafirlukast (ICI 204219) 是一种白三烯 D4 受体 (LTD4) 拮抗剂 (IC50=0.6 μM),具有口服活性。Zafirlukast 具有平喘、抗炎和抗菌作用,被用于哮喘的预防和治疗。

Zafirlukast
其他形式的 “Zafirlukast”:
TargetMol

为众多的药物研发团队赋能,

让新药发现更简单!

Zafirlukast

一键复制产品信息
Rating icon 很棒

纯度: 99.83%

货号 T6736 别名 扎鲁司特, Vanticon, ICI 204219, AccolateCas号 107753-78-6

Zafirlukast (ICI 204219) 是一种白三烯 D4 受体 (LTD4) 拮抗剂 (IC50=0.6 μM),具有口服活性。Zafirlukast 具有平喘、抗炎和抗菌作用,被用于哮喘的预防和治疗。

规格价格库存数量
2 mg
¥ 123
现货
5 mg
¥ 183
现货
10 mg
¥ 256
现货
25 mg
¥ 389
现货
50 mg
¥ 549
现货
100 mg
¥ 798
现货
500 mg
¥ 2,380
5日内发货
1 mL x 10 mM (in DMSO)
¥ 282
现货
库存状态实时更新,以官网显示为准,现货产品可直接加购物车下单
大包装 & 定制
加入购物车
TargetMol的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。
实验操作小课堂
常见问题解答
查看更多
选择批次:
纯度: 99.75%
联系我们 获取更多批次信息

产品介绍


Zafirlukast AI Summary
Zafirlukast is a potent antagonist of the Cysteinyl leukotriene D4 (LTD4) receptor, exhibiting a high binding affinity with a Ki value of 0.3 nM. It significantly inhibits LTD4-induced contraction in guinea pig tracheal strips with a Kd of 0.3162 nM and demonstrates an IC50 value of 1.03 nM for blocking contractile effects. In vivo, the compound reduces LTD4-induced bronchoconstriction, showing initial activity level reduction from 117.0 to a sustained 5.0 over 24 hours. Additionally, Zafirlukast has an effective dose (ED50) of 0.9 mg.kg-1 for alleviating antigen-induced airway obstruction in guinea pigs and exhibits bioavailability with F values of 67.0% in dogs and 68.0% in rats. Beyond its primary action on leukotriene pathways, Zafirlukast also inhibits calcium mobilization in human U937 cells with an IC50 of 1.0 nM and has demonstrated involvement in various other biological pathways. Although the compound shows no significant activity on multiple other receptors and enzymes, it does bind to cytochrome P450 2C9 (Ki = 2500 nM) and exhibits hepatotoxic properties indicated by high liver toxicity scores and inhibition of BSEP, MRP2, and MRP4 transporters. Pharmacokinetic studies reveal important metrics such as Tmax between 2.0 to 3.0 hours, Cmax ranging from 566.28 to 1313.21 nM, T1/2 between 8.0 to 13.3 hours, and high plasma protein binding at 99.0%. The compound also influences various metabolic and enzyme pathways, notably inducing CYP3A4 via PXR activation. It inhibits the uptake of ASP+ by human OCT2, MATE1, and MATE2K transporters and has demonstrated moderate to weak antiviral activity against SARS-CoV-2. This profile suggests Zafirlukast's potential therapeutic applications in respiratory disorders involving leukotriene-mediated pathways, although its liver toxicity and broad biological interactions warrant careful consideration..
Note: Summary generated by AI. Data source: ChEMBL
生物活性
产品描述
Zafirlukast (ICI 204219) is an orally active leukotriene D4 receptor (LTD4) antagonist (IC50=0.6 μM). Zafirlukast has anti-asthmatic, anti-inflammatory, and antimicrobial properties and is used in the prevention and treatment of asthma.
体外活性

方法:肺腺癌细胞 LA795 用 Zafirlukast (25-100 µM) 处理 48 h,通过 MTT assay 测定细胞活力。
结果:Zafirlukast ZAF浓度依赖性地抑制 LA795 细胞的增殖,50、75 和 100 µM 的 Zafirlukast 分别使 LA795 细胞的增殖能力降低了 27.3%、55.5% 和 67.3%。[1]
方法:乳腺癌细胞 MDA-MB-231 用 Zafirlukast (20 µM) 处理 1-37 h,通过 scratch assay 检测细胞迁移。
结果:与 1 h 时获得的面积值相比,载体处理的细胞在终点时迁移到覆盖超过 86% 的划痕区域,而 Zafirlukast 处理的细胞迁移明显减弱,在终点时覆盖了 56% 的划痕区域。[2]

体内活性

方法:为检测体内抗肿瘤活性,将 Zafirlukast (2.9-5.8 mg/kg) 腹腔注射给携带 LA795 异种移植物的 BALB/c nude 小鼠,每两天一次,给药七次。
结果:高剂量 Zafirlukast 的实验组肿瘤生长速度最慢。Zafirlukast 对肿瘤移植小鼠肺腺癌肿瘤的生长具有显著的抑制作用。Zafirlukast 对小鼠体重没有显著影响。[1]

别名扎鲁司特, Vanticon, ICI 204219, Accolate
化学信息
分子量575.68
分子式C31H33N3O6S
CAS No.107753-78-6
SmilesCOc1cc(ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12)C(=O)NS(=O)(=O)c1ccccc1C
密度1.32 g/cm3 (Predicted)
储存&溶解度
存储store at low temperature | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
溶解度信息
DMSO: 105 mg/mL (182.39 mM), Sonication is recommended.
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
H2O: < 1 mg/mL (insoluble or slightly soluble)
体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (6.95 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
溶液配制表
DMSO
1mg5mg10mg50mg
1 mM1.7371 mL8.6854 mL17.3708 mL86.8538 mL
5 mM0.3474 mL1.7371 mL3.4742 mL17.3708 mL
10 mM0.1737 mL0.8685 mL1.7371 mL8.6854 mL
20 mM0.0869 mL0.4343 mL0.8685 mL4.3427 mL
50 mM0.0347 mL0.1737 mL0.3474 mL1.7371 mL
100 mM0.0174 mL0.0869 mL0.1737 mL0.8685 mL

计算器

  • 摩尔浓度 计算器
  • 稀释 计算器
  • 配液 计算器
  • 分子量 计算器

体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:
比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL
母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
方案所需的各类助溶剂如: DMSOPEG300PEG400Tween 80SBE-β-CD玉米油等, 均可在TargetMol网站点击购买。
1 请输入动物实验的基本信息
mg/kg
g
μL
2 请输入动物体内配方组成,不同的产品配方组成不同,如有配方需求,可先联系我们提供正确的体内配方。
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

剂量转换

对于不同动物的给药剂量换算,您也可以参考 更多

Related Tags: buy Zafirlukast | purchase Zafirlukast | Zafirlukast cost | order Zafirlukast | Zafirlukast chemical structure | Zafirlukast in vivo | Zafirlukast in vitro | Zafirlukast formula | Zafirlukast molecular weight